IL17A and psoriasis: Although immune targeting of IL-17 and IL-23 cytokines by biological agent therapy currently shows significant efficacy, this efficacy is insufficient, and the treatment lacks clinical response in individuals and fails to prevent the recurrence of psoriasis [64].